Market Intel: Voyage Into Point-Of-Care Testing Gets Deeper
Diagnostic testing is increasingly moving from centralized laboratories into pharmacies, physicians' offices, hospitals and directly to consumers as part of the transition to value-based care with its focus on providing quality care at a lower cost. Point-of-care testing (POCT) – and what it means for the future of health-care delivery, health-care providers and creators of innovative technologies joining forces to satisfy consumers' growing appetite for convenient and rapid testing – took centerstage at the recent AACC Annual Meeting in San Diego. This feature takes a closer look at the increasing migration of POCT into the retail arena, specifically pharmacies, to support primary-care providers, along with its challenges. It also highlights emerging trends and technologies, including presentations of the "Star Trek-like" innovations from the Qualcomm Tricorder XPrize competition winners that are bound to disrupt the landscape of direct-to-consumer testing. We also provide expert opinions of the pros and cons of bringing POC services closer to consumers.
You may also be interested in...
Market Intel: From AI-Based IVDs To Precision Drug Dosing: Medtech Conference 2017 Gives Insight Into Tomorrow's Technologies
The annual AdvaMed conference, rebranded "Medtech Conference" this year, drew more than 2,700 attendees seeking to explore cutting-edge technologies and networking opportunities, as well as to hear from FDA's top officials about new developments. This article takes a closer look at some of the most innovative solutions presented at the event, including machine learning-based diagnostics to combat antimicrobial resistance, a ureter-locating device, virtual reality technologies to enhance orthopedic surgery and precision drug dosing, among other things.
Market Intel: Artificial Intelligence Brings Wave Of Future Health Care Innovation – Embrace it or be Left Behind
Artificial intelligence and machine-learning will be the biggest disrupters in the health care industry, forcing a major shift in how companies innovate and operate, offering physicians unprecedented tools to diagnose and treat patients to improve outcomes and connecting patients like never before through consumer-driven devices. This feature takes a close look at how smaller companies and giants like Abbott, as well as national health care systems, are leveraging the power of AI to expedite innovation and product development in diabetes and other diseases. It highlights some of the latest studies that show how AI is being harnessed to improve imaging analytics, predict hard-to-find risk factors for heart disease and detect cancer, and discusses the critical role tech giants such as IBM, Google and Amazon continue to play in this space.
The 18% of FY 2015 PMA and HDE device approvals that included pediatric indications was the lowest proportion since FY 2009, even while, overall, 2015 was a record-setting year for novel device approvals.